Anticoagulation alone as an effective and safe antithrombotic therapy in LVAD: When less is more.
Journal
Current problems in cardiology
ISSN: 1535-6280
Titre abrégé: Curr Probl Cardiol
Pays: Netherlands
ID NLM: 7701802
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
03
11
2022
accepted:
11
11
2022
pubmed:
20
11
2022
medline:
4
1
2023
entrez:
19
11
2022
Statut:
ppublish
Résumé
To evaluate the safety and effectiveness of anticoagulation alone in HeartMate3 patients. According to antithrombotic regimen, patients were divided into 2 groups: Group-1(warfarin+aspirin) and Group-2(warfarin). A comparison of hemocompatibility-related adverse events (HRAEs), hemocompatibility score (HCS), and hemocoagulative laboratory markers, both qualitative and quantitative, between the 2 groups were performed. Fifty patients were enrolled, 28 (56%) in Group-1 and 22 in Group-2 (44%), without statistical differences at baseline. Median time of follow-up was 590 days (IQR: 410.25-1007.50). Eighteen HRAEs (36.0%) occurred: 17 in Group-1 (34%) and 1 in Group-2 (2%) (P < 0.001). The net HCS for Group-1 versus Group-2 was 24 points and 1 point (OR 12.116[2.034-233.226], P = 0.023), respectively. Hemocoagulative values turned into the normality and remained stable during follow-up, without differences between groups, except for ASPI-test (P = 0.003). HeartMate3 showed a high hemocompatibility independently from antithrombotic therapy. Aspirin avoidance resulted a safe and effective strategy since it reduced hemorrhagic events, without increasing thrombotic risk.
Identifiants
pubmed: 36402214
pii: S0146-2806(22)00403-0
doi: 10.1016/j.cpcardiol.2022.101506
pii:
doi:
Substances chimiques
Warfarin
5Q7ZVV76EI
Fibrinolytic Agents
0
Anticoagulants
0
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101506Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.